Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

Medically reviewed by Nicholas R. Metrus, MD Multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) are both diseases that affect your central nervous system ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Stanford University scientists have developed a brain implant designed to "hear" and vocalize words a person with severe ...

Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, with an incidence of 1 or 2 cases per 100,000 persons and a lifetime risk of 1 case per 800 persons.